Deutsche Bank analyst David Hoang downgraded Apogee Therapeutics Inc (NASDAQ: APGE) from Buy to Hold with a price target of $135.00 (from $116.00).

For an analyst ratings summary and ratings history on Apogee Therapeutics Inc click here. For more ratings news on Apogee Therapeutics Inc click here.

Shares of Apogee Therapeutics Inc closed at $90.38 yesterday.